 SOUTH SAN FRANCISCO, Calif., April 28, 2021 GLOBE NEWSWIRE -- UNITY Biotechnology, Inc. UNITY NASDAQ: UBX, a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, will present preclinical data on its lead clinical candidate, UBX1325, at the Association for Research in Vision and Ophthalmology ARVO 2021 Annual Meeting, being held May 1-7, 2021. In addition, Przemyslaw Mike Sapieha, Ph.D., chief scientific advisor for UNITY, will participate in a special interest panel on diabetic retinopathy. 